Study: Rare mutations in PALB2, CHEK2, and ATM: how much do they increase cancer risk?


This article is most relevant for:
People who tested positive for one of the rare variants in CHEK2, ATM or PALB2 that are covered in this study

This article is also relevant for:

Checked People with a genetic mutation linked to cancer risk

Checked Previvors

Checked Other mutations: People with very rare mutations in PALB2, CHEK2, and ATM


Be a part of XRAY

Relevance: Medium-High

Relevance

Strength of Science: Medium

Strength of Science

Research Timeline: Post Approval

Research Timeline

Rating Details

Read the article

Printer Friendly Page

As multi-gene panel tests become more common, people are discovering they have mutations in genes that are not understood as well as BRCA. This can make it difficult to give patients accurate assessments of their cancer risk. For example, mutations in PALB2, CHEK2, and ATM are rare, but some specific changes in these genes are even less common. The goal of this international collaboration was to better understand the cancer risks of some very rare PALB2, CHEK2, and ATM mutations. The findings are relevant only to the specific mutations covered in this paper and do not apply to all people with mutations in PALB2, CHEK2, or ATM. (9/27/16)

Contents

At a glance Questions for your doctor
Findings                In-depth                 
Clinical trials Limitations
Guidelines Resources and references


STUDY AT A GLANCE

This study is about:

The breast, ovarian, and prostate cancer risks associated with rare mutations in PALB2, CHEK2, and ATM.

Why is this study important?

Some mutations in PALB2, CHEK2, and ATM are rare, making it difficult to determine the exact increased cancer risk for people who carry them. Patients with these mutations need to know this information so that they and their healthcare providers can make appropriate decisions about their cancer screenings and treatment.

Study findings: 

  1. PALB2 mutations: There were three rare PALB2 mutations studied.
    • Two were associated with an increased risk of breast cancer, and one was not.
    • None of the three rare PALB2 mutations studied were associated with increased prostate or ovarian cancer risk.
  2. ATM mutations:
    • One rare ATM mutation was associated with an increased risk of breast cancer, but not with prostate or ovarian cancer.
  3. CHEK2 mutations: There were six rare CHEK2 mutations studied.
    • Four were associated with increased breast cancer risk, although the risk was not as high as those found in some of the PALB2 and ATM mutations. 
    • One mutation was not associated with increased breast cancer risk for European women, but was associated with increased prostate cancer risk for European men.
    • One mutation that was only found in African men and women was associated with both increased breast cancer and prostate cancer risk.
    • None of the six mutations were associated with an increased risk for ovarian cancer.     

What does this mean for me?

It is important to remember that this study looked at just a handful of rare mutations in ATM, CHEK2 and PALB2, and cannot be used to draw conclusions about all mutations in these genes. However, this work indicates that it is important to know the exact mutation a patient has, as well as his/her personal and family history of cancer when developing a plan for cancer screening or assessing potential treatment options. More work needs to be done to confirm some of these findings, and to determine other rare mutations that may increase a patient’s cancer risk or not have an effect on a patient’s cancer risk. Patients should work with their healthcare providers to understand their genetic test results and determine what screenings and treatments are best for them.

(back to top)

Expert Guidelines

The National Comprehensive Cancer Network (NCCN) brings together a panel of experts to  create guidelines for genetic testing for inherited mutations that increase cancer risk. NCCN Guidelines for women with mutations in PALB2, NBN, BRIP1 and other genes include the following:

Breast Cancer Screening: 

  • Annual screening mammogram (consider 3D mammography) and annual MRI with contrast beginning at age 30, or earlier based on family breast cancer history for women with mutations in following genes:
    • PALB2
    • CDH1
    • NF1
  • Annual screening mammogram (consider 3D mammography) and annual MRI with contrast beginning at age 40, or earlier based on family breast cancer history for women with mutations in following genes:
    • ATM
    • CHEK2
    • NBN

Breast Cancer Risk Management

  • Discussing the option of risk-reducing mastectomy based of family history of breast cancer for women with mutations in:
    • ATM
    • CHEK2
    • NBN
    • NF1
    • PALB2

It is important for people with mutations in these genes to consult with a genetics expert to determine the best risk management plan based on their personal and family medical history and other circumstances. 

Questions To Ask Your Health Care Provider

  • I was diagnosed with breast cancer before age of 45; should I consider genetic testing?
  • I tested negative for mutations in BRCA1 and BRCA2, despite being diagnosed with breast cancer before the age of 45; should I consider additional genetic testing?
  • Members of my family have a mutation in PALB2, CHEK2, or ATM; should I consider genetic testing?
  • I tested positive for a mutation in a gene for which cancer risk is not well understood; how can I be sure I get new information on my cancer risk as more research is completed?
  • Can you refer me to a genetics expert?

Open Clinical Trials

  • NCT02665195: Prospective Registry of Multiplex Testing (PROMPT). This study is being done to learn more about how changes in certain genes may be linked to cancer. The want to better understand the risks that are linked to genetic changes in these less well-studied genes in order to give better advice to families with mutations in these genes.
  • Breast Cancer Treatment in Women with PALB2 Mutations. The PALB2 Study is an international research study to better understand breast cancer treatment among women with a PALB2 gene mutation. Participants are asked to complete online or paper study questionnaires (every two years for 10 years) and share their family history, medical, and genetics records.
  • NCT03805919: Men at High Genetic Risk for Prostate Cancer. The National Cancer Institute recently opened a clinical trial for prostate cancer screening in men who may be at high risk for prostate cancer due to an inherited mutation in BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), CHEK2, PALB2, RAD51D, or FANCA. 

IN DEPTH REVIEW OF RESEARCH

Study background:

Many multi-gene panel tests look for mutations in PALB2, CHEK2, and ATM. However, while mutations in these genes are rare, some versions of the mutations are even less common. Our current understanding of cancer risk associated with mutations in PALB2, CHEK2, and ATM results from studying the most common mutations in these genes. From this past work, researchers realized that in some cases, mutations in PALB2 could increase cancer risk as much as a mutation in a BRCA gene, while mutations in CHEK2 and ATM increase cancer risk to a lesser extent but above the level of an average person.

Studying rare mutations is difficult because the study has to be large enough to see how mutations in these genes affect cancer risk. Yet researchers have a hard time finding enough people with these rare mutations to study cancer risk and draw conclusions that can be used to make cancer risk management decisions.

Melissa Southey and her colleagues from The University of Melbourne and other institutions around the world published work in the Journal of Medical Genetics in June 2016 that assessed the cancer risk associated with a handful of specific, very rare mutations in PALB2, CHEK2, and ATM.

Researchers of this study wanted to know:

What are the breast, ovarian, and prostate cancer risks associated with rare mutations in PALB2, CHEK2, and ATM?

Population(s) looked at in the study:

The participants in this study were from studies participating in three consortiums:

  • The Breast Cancer Association Consortium (BCAC)
    • The majority of women in the studies from this consortium were of European ancestry (42,671 cases and 42,164 controls), compared to Asians (5,795 cases and 6,624 controls), and African Americans (1,046 cases and 932 controls). All of the women had invasive breast cancer.
  • The Prostate Cancer Association Group to Investigate Cancer Alterations in the Genome (PRACTICAL)
    • The majority of men in the studies from this consortium were of European ancestry (22,301 cases and 22,320 controls), compared to African American men (623 cases and 569 controls).
  • The Ovarian Cancer Association Consortium (OCAC)
    • The majority of women in the studies from this consortium were of European ancestry (16,287 cases and 14,542 controls), compared to Asian women (720 cases and 93 controls), and African American women (150 cases and 36 controls).

These consortiums are all part of the Collaborative Oncological Gene-environment Study (COGS) with a total of 176,873 participants.

Study findings: 

  1. PALB2 mutations: There were three rare PALB2 mutations studied.
    • Two mutations were associated with increased breast cancer risk (PALB2 c.1592delT and PALB2 c.3113G>A),  while one was not (PALB2 c.2816T>G).  In all, 41 people were found to have the PALB2 c.1592delT mutation, 52 people had the PALB2 c.3113G>A mutation, and 295 people had the PALB2 c.2816T>G mutation.
    • None of the three rare PALB2 mutations studied showed an association with increased prostate or ovarian cancer risk.
  2. ATM mutations:
    • The one rare ATM mutation (ATM c.7271T>G) studied was found to be associated with an increased risk of breast cancer, but not for prostate or ovarian cancer; only 13 people in this study had this mutation.
  3. CHEK2 mutations: There were six rare CHEK2 mutations studied.
    • Four mutations  (CHEK2 c.349A>G, CHEK2 c.538C>T, CHEK2 c.715G>A, CHEK2 c.1036C>T) were associated with increased breast cancer risk, although the risk was not as high as the PALB2 and ATM mutations studied. The study showed that 62 people had the CHEK2 c.349A>G mutation, 300 people had the CHEK2 c.538C>T mutation, 24 people had the CHEK2 c.715G>A, and 11 people had the CHEK2 c.1036C>T mutation.
    • One mutation (CHEK2 c1312G>T) was not associated with increased breast cancer risk for European women, but was associated with increased prostate cancer risk for European men; 34 people in this study had this mutation.
    • One mutation (CHEK2 c.1343T>G) was only found in African men and women, and was associated with increased breast cancer and prostate cancer risk; 46 people in this study had this mutation.
    • None of the six mutations were associated with an increased risk for ovarian cancer.           

Limitations:

The cancer risks calculated in this study apply to very few people because, of the hundreds of mutations that can occur in PALB2, CHEK2, and ATM, the study looked at only 10 specific mutations.  Because these are rare mutations, the sample size for some of them was too small, even from an international collaboration, to yield a definitive conclusion (especially as seen in the mutations that were carried by less than 20 people). Additionally, the international approach does not greatly improve the risk estimates for the mutations that are only found in certain populations (such as the CHEK2 mutation that was only found in African American patients). This means that the cancer risks calculated in this study might not apply to the few people who have one of these rare mutations.  Finally, it is always important to remember mutation status is not the only measure of increased cancer risk. Even if a person has a mutation that was found to not increase cancer risk in this study, there are other factors that are involved in determining cancer risk including family history and lifestyle factors

Conclusions:

The results of this study suggest that some of the rare mutations in PALB2 and ATM may be associated with increased risk of breast cancer, putting these women at “high risk.” This indicates that these women should have more screening and should discuss risk-reducing measures with their health care providers. However, more work needs to be done, especially in developing more methods that can be used to estimate these risks accurately for these rare mutations that are difficult to study with human populations.  This study is a clear example of how much work and how many research participants are needed to get reliable estimates of cancer risks associated with specific mutations.

It is important to note that this study looked at a handful of specific mutations in PALB2, CHEK2, or ATM; it did not look at the risk of having any mutation in these genes. People with mutations in PALB2, CHEK2, or ATM should consult with a genetics expert who can look at both their gene mutation as well as their personal and family history of cancer to help them estimate their cancer risk.

Posted 9/27/16

Share your thoughts on this XRAYS article by taking our brief survey.

7 likes

Back to XRAY Home

Search XRAY studies and articles

Back to XRAY Home

FORCE:Facing Our Risk of Cancer Empowered